GREY:IPHAF - Post by User
Comment by
professional11on Feb 05, 2010 7:09pm
530 Views
Post# 16758120
Novartis/Alcon, Roche implications
Novartis/Alcon, Roche implicationshttps://www.fiercepharma.com/story/novartis-shopping-its-roche-stake/2010-02-03
Novartis is selling off its Roche shares to pay for the Alcon purchase. This is good news for ISA and Lux. Novartis/Alcon (#1 in kidney transplant, #1 in eye drugs) is soon going to be a 100% competitor with Roche.
If Voclosporine receives FDA-approval in October, look for Novartis/Alcon to purchase ISA/Lux by years end. And the sweet irony would be that a portion of the $9B Novartis would get for their Roche shares will pay for it.
P11